

## ICMJE DISCLOSURE FORM

Date: 16 August 2021

Your Name: Dr. LAM Wai Kei Jacky

Manuscript Title: Plasma Epstein-Barr virus DNA analysis for personalized management of nasopharyngeal carcinoma – current opportunities and challenges

Manuscript number (if known): ANPC-21-11

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Theme-based Research Scheme (T12-401/16-W) under the Research Grants Council of the HKSAR Government	Payments were made to the institution.
		Collaborative research agreement from Grail	Payments were made to the institution.
		Innovative and Technology Fund under the InnoHK Initiative	Payments were made to the institution.
		Vice Chancellor’s One-Off Discretionary Fund of the Chinese University of Hong Kong (VCF2014021)	Payments were made to the institution.
<b>Time frame: past 36 months</b>			

2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	Grail, Inc.	I served as a consultant to Grail, Inc. from Feb 2018 to Jan 2019
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	Yes	I have filed multiple patent applications on circulating nucleic acids analysis for cancer diagnostics.
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	Grail, Inc.	I hold stock options in Grail, Inc.
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

**Please summarize the above conflict of interest in the following box:**

This work was supported by the Research Grants Council of the Hong Kong SAR Government under the Theme-based research scheme (T12-401/16-W), a collaborative research agreement from Grail, the Innovation and Technology Fund under the *InnoHK* Initiative and the Vice Chancellor's One-Off Discretionary Fund of The Chinese University of Hong Kong (VCF2014021). Y.M.D. Lo is supported by an endowed chair from the Li Ka Shing Foundation.

**Please place an "X" next to the following statement to indicate your agreement:**

**I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: 16 August 2021

Your Name: Prof. LO Yuk Ming Dennis

Manuscript Title: Plasma Epstein-Barr virus DNA analysis for personalized management of nasopharyngeal carcinoma – current opportunities and challenges

Manuscript number (if known): ANPC-21-11

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Theme-based Research Scheme (T12-401/16-W) under the Research Grants Council of the HKSAR Government	Payments were made to the institution.
		Collaborative research agreement from Grail	Payments were made to the institution.
		Innovative and Technology Fund under the InnoHK Initiative	Payments were made to the institution.
		Vice Chancellor’s One-Off Discretionary Fund of the Chinese University of Hong Kong (VCF2014021)	Payments were made from the institution to the authors’ department.
		Li Ka Shing Foundation	endowed chair
<b>Time frame: past 36 months</b>			

2	Grants or contracts from any entity (if not indicated in item #1 above).	____ None	
3	Royalties or licenses	Grail, Inc.	
		Illumina	
		Sequenom	
		DRA	
		Take2 Group of companies	
		Xcelom	
4	Consulting fees	Grail, Inc.	I serve as a consultant to Grail, Inc.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	____ None	
6	Payment for expert testimony	____ None	
7	Support for attending meetings and/or travel	____ None	
8	Patents planned, issued or pending	Yes	I have filed multiple patent applications on circulating nucleic acids analysis for cancer diagnostics.
9	Participation on a Data Safety Monitoring Board or Advisory Board	____ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Grail, Inc.	I am a scientific advisory board member of Grail, Inc.
		Take2 Group of companies	I am a board member of the Take2 Group of companies
		Decheng Capital	I am an advisor of Decheng Capital
11	Stock or stock options	Grail, Inc.	
		DRA	
		Take2 Group of companies	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	____ None	
13	Other financial or non-financial interests	____ None	

**Please summarize the above conflict of interest in the following box:**

This work was supported by the Research Grants Council of the Hong Kong SAR Government under the Theme-based research scheme (T12-401/16-W), a collaborative research agreement from Grail, the Innovation and Technology Fund under the *InnoHK* Initiative and the Vice Chancellor's One-Off Discretionary Fund of The Chinese University of Hong Kong (VCF2014021). Y.M.D. Lo is supported by an endowed chair from the Li Ka Shing Foundation.

Y.M.D. Lo is a scientific co-founder, shareholder, scientific advisory board member and consultant of, and receives research support from Grail. Y.M.D. Lo is a founder, shareholder and board member of the Take2 Group of companies and DRA Limited, and an advisor of Decheng Capital.

**Please place an "X" next to the following statement to indicate your agreement:**

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.